Nice | Tolvaptan for treating autosomal polycystic kidney disease

15th February 2016 by Louise Hudman

Nice | Tolvaptan for treating autosomal polycystic kidney disease

This is a new guideline from NICE advising that tolvaptan can be used for treating autosomal polycystic kidney disease. It is a selective vasopressin antagonist which can reduce cell proliferation, cyst formation and fluid excretion. This reduces kidney growth and protects renal function.

Patients need to have:

  • CKD 2 or 3
  • Rapidly progressing disease

It has several side-effects, including polyuria, nocturia and frequency of urination. It can also be hepatotoxic and can elevate liver function tests.

MIMS Learning | Chronic kidney disease: clinical review

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I started working as a locum GP in January this year and NASGP have been invaluable in helping to co-ordinate my bookings and organise all the administrative aspects of sessional work which can be complex and time consuming. Their client support is outstanding and they have always resolved any queries promptly and personally. They care about the service they provide and I would not hesitate to recommend them to any sessional GPs who want to minimise time spent on administration and focus on providing patients with high quality care."

Dr Paul Riley, Locum GP

Dr Paul Riley, Locum GP

See the full list of features within our NASGP membership plans

Membership